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Background: Mannan-binding lectin (MBL), a protein of the innate immune response is attracting increasing
clinical interest, in particularly in relation to its deficiency. Due to its involvement in brain diseases, identifying the
source of MBL in CSF is important. Analysis of cerebrospinal fluid (CSF) can provide data that discriminates between
blood-, brain-, and leptomeninges-derived proteins. To detect the source of MBL in CSF we need to consider three
variables: the molecular size-dependent concentration gradient between CSF and blood, the variation in transfer
between blood and CSF, and the CSF MBL concentration correlation with the albumin CSF/serum quotient (QAlb),
i.e., with CSF flow rate.
Methods: MBL was assayed in samples of CSF and serum with an ELISA, coated with anti MBL antibodies. Routine
parameters such as albumin-, immunoglobulin- CSF/serum quotients, oligoclonal IgG and cell count were used to
characterize the patient groups. Groups comprised firstly, control patients without organic brain disease with
normal CSF and normal barrier function and secondly, patients without inflammatory diseases but with increased
QAlb, i.e. with a blood CSF barrier dysfunction.
Results: MBL concentration in CSF was at least five-fold higher than expected for a molecular-size-dependent
passage from blood. Secondly, in a QIgM/QAlb quotient diagram (Reibergram) 9/13 cases showed an intrathecal
fraction in some cases over 80% of total CSF MBL concentration 3) The smaller inter-individual variation of MBL
concentrations in CSF of the control group (CV = 66%) compared to the MBL concentrations in serum (CV = 146%)
indicate an independent source of MBL in CSF. 4) The absolute MBL concentration in CSF increases with increasing
QAlb. Among brain-derived proteins in CSF only the leptomeningeal proteins showed a (linear) increase with
decreasing CSF flow rate, neuronal and glial proteins are invariant to changes of QAlb.
Conclusions: MBL in CSF is predominantly brain-derived and all results pointed to the leptomeningeal cells as the
source of the protein. The evaluation of this protein requires the interpretation of its absolute concentrations in CSF
as a function of the albumin quotient, QAlb. This recognition of MBL in brain cells opens a new field of discussion
about the function of the innate immune response in CNS in cases of acute and chronic neurological diseases.
Keywords: CSF, CSF Flow, Protein dynamics, Blood-derived proteins, Brain-derived proteins, Leptomeninges,
Mannan binding lectin, Innate immune system in CNS, Blood- CSF barrier functionBackground
Blood-CSF barriers and CSF flow rate
Increased protein concentrations in the cerebrospinal
fluid (CSF) of patients with neurological diseases, fre-
quently ascribed to a blood-CSF barrier dysfunction, are
due to pathologically-reduced CSF flow rates [1]. This
view is based on the molecular diffusion/CSF flow theory* Correspondence: ho@horeiber.de
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reproduction in any medium, provided the or[1] which shows that the concentration of a blood-
derived protein in CSF is in equilibrium between the
rate of diffusion into CSF and rate of elimination by CSF
flow. The molecular size-dependent rate of diffusion is
represented by the CSF/serum concentration quotients
of the purely blood-derived proteins in normal CSF.
Albumin in CSF is derived exclusively from blood even
in all kinds of pathological processes of neurological dis-
ease [1,2]. Therefore albumin became the generally
accepted reference for the individual barrier function for
blood-derived proteins (such as IgG, or IgM) in the formLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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there are no transport systems for the passage for pro-
teins from blood to CSF, the CSF/serum quotient of a
blood-derived fraction of any protein molecule for which
we know the molecular size can be estimated [1,4]. With
this concept, which shows that a blood-CSF barrier dys-
function is not any kind of “leakage” at capillary struc-
tures but a consequence of the pathologically-reduced
CSF flow rate, a change in QAlb can be interpreted as a
change in CSF flow rate [1,4]. With this much wider
view of the barrier function for proteins, it is necessary
to extend our view from the blood-derived proteins to
all proteins in CSF. But the influence of reduced CSF
flow rate on proteins in CSF depends critically on the
source of the proteins.
Sources of CSF proteins
Three sources for CSF proteins can be identified. These
are: firstly, blood-derived proteins in CSF (80% of total
protein [2]) evaluated as CSF/serum quotients with
reference to the albumin CSF/serum concentration quo-
tient, QAlb (e.g. IgG, IgA, and IgM) [2,3]. The non lin-
ear reference range for blood-derived proteins in CSF
forms the base for Reibergrams [2,3,5], which enables
the sensitive and quantitative detection of additional
intrathecal synthesis [3]. Secondly, brain cell- derived
proteins are interpreted by their absolute concentration
in CSF without reference to QAlb, since they are inde-
pendent of CSF flow rate (e.g. Tau protein, S-100 B,
neuron-specific enolase [4,6]). Thirdly, proteins are
released from leptomeningeal cells into CSF. These are
also evaluated as absolute CSF concentration but with
additional reference to QAlb, because they have a linear
correlation with CSF flow rate (e.g. beta trace protein,
cystatin C [4,6]).
Inappropriate referencing of brain-derived proteins to
their serum concentration using the CSF/serum quo-
tient instead of the absolute CSF concentration leads to
a loss of sensitivity for discriminations between groups,
i.e., eventually to false interpretations of CSF data and
disease pathologies. These different dynamics in CSF
have been shown empirically and were derived quanti-
tatively from the molecular diffusion/CSF flow model
of Reiber [1,4,6]. This mathematical derivation from
the laws of diffusion also explains the rostro-caudal
concentration gradients which increase for blood-
derived and decrease for brain cell-derived proteins in
CSF, again with a particular variation for leptomenin-
geal proteins [4,6]. From these considerations it is pos-
sible to discriminate between the different sources of
CSF proteins for diagnostic purposes. As a particular
analytical tool for discrimination between blood- and
brain-derived proteins, we have used in this evaluation
the variation propagation, expressed as the coefficientof variation for the inter-individual variation between
blood and CSF concentrations in a control group of
patients.
Mannan-binding lectin (MBL)
The increasing awareness for the innate immune sys-
tem and its possible role in the CNS is documented
in recent publications (cited in [7,8]): Mannan-binding
lectin (MBL) [7] is of increasing clinical interest, since
MBL deficiency [8] was found to be associated with
different diseases, including infections, in systemic as
well as neurological diseases [8-11]. MBL, a collage-
nous serum lectin (collectin), synthesized in the liver
is believed to play an important role in innate immun-
ity. The innate immune system is non-clonal and
recognizes conserved patterns (pathogen-associated
molecular patterns) on e.g. bacteria and yeast by
genetically-encoded pattern recognition molecules.
MBL thus recognizes patterns of mannose, glucose
and N-acetyl-glucosamine residues on microbial cell
walls. The binding of MBL to suitably spaced patterns
of glycosylation initiates the activation of the comple-
ment cascade through MBL-associated serine proteases
(MASPs) [7,12,13].
In previous studies MBL has been detected in CSF
[10,14]. In this study, we evaluated the possibility that
CSF MBL originates from within the brain, using data
from two patient groups: a control group with normal
QAlb, i.e., normal blood-CSF barrier function, and a sec-




Lumbar CSF and serum samples originated from
patients of the Department of the Neurological Univer-
sity Hospital, Goettingen. All samples were taken for
routine analysis [2,3], indicated by diagnostic criteria
with the informed consent of the patients. As no experi-
ments with patients were involved, we did not ask for
ethical approval. Nevertheless, after routine analysis, re-
sidual CSF and serum samples, stored throughout at 4°
C, were made anonymous according to the general ad-
vice of the ethics committee of the Medical Faculty, Uni-
versity Goettingen. From these samples we selected
retrospectively two groups for this study: a) Normal con-
trols (N = 13) and b) Cases of barrier dysfunctions with-
out intrathecal immune response (N= 7). Control
patients were referred for lumbar puncture on clinical
indications, but were determined to be normal with no
indication of organic brain disease according to clinical
and imaging criteria, e.g. tension headache or non-
inflammatory polyneuropathies, and according to their
CSF and blood data (normal CSF leukocyte count and
Figure 1 Immunoglobulin and Albumin quotient diagrams
(Reibergrams) of the normal controls (filled squares) and
patients with blood-CSF barrier dysfunctions without an
intrathecal immune response (open circles). Oligoclonal IgG was
absent in all patients, also in the one patient with a borderline IgM
quotient. The age-related reference range for normal QAlb values
(normal blood-CSF barrier function) was calculated according to the
formula QAlb < (4+ age (years)/15) × 10-3. An intrathecal synthesis of
IgG, IgA and IgM is indicated by quotient values above the
hyperbolic upper limit curve, Qlim (bold line). The reference range
for the blood–derived fractions in CSF is derived from data of 4300
patients (mean± 3SD [1], corresponding to 99% probability of
intrathecal synthesis if QIg >Qlim). The dashed lines above Qlim
indicate the extent of the intrathecally synthesized fractions in%
with reference to Qlim as 0% [3]. These diagrams are developed for
maximal specificity for intrathecal synthesis with the Qmean+ 3SD.
For statistical comparison of mean values of groups the calculation
refers to Qmean and for counting the frequencies of intrathecal
fractions of the group we refer to Qmean+ 2 SD (CSF Statistics Tool
[15], with which also the diagram was created).
Reiber et al. Fluids and Barriers of the CNS 2012, 9:17 Page 3 of 7
http://www.fluidsbarrierscns.com/content/9/1/17protein values, no oligoclonal IgG, age-related normal
albumin quotient, normal blood leukocytes and serum
C-reactive protein, CRP). The immunoglobulin data are
shown in the quotient diagrams (Figure 1, Reibergrams).
Patients with non-inflammatory diseases but with
blood–CSF barrier dysfunction had increased CSF/
serum albumin quotients (QAlb) as well as all other
blood-derived CSF/serum protein quotients (QIgG,
QIgA, QIgM) but without any intrathecal contribution
to the CSF values, as shown in the quotient diagrams
(Figure 1, Reibergrams). Oligoclonal IgG in CSF and
intrathecal IgG, IgA or IgM synthesis were exclusion cri-
teria. Patients in this group typically had spinal canal
stenosis, spinal tumor or disc prolapse. They had normal
CSF cell counts and typical findings in electromyography
and magnetic resonance tomography of the spine.
Routine analysis of CSF
Analysis of albumin, immunoglobulins IgG, IgA, IgM
in CSF and serum, oligoclonal IgG and cell count was
performed as described earlier [2,3]. The age-related
reference range for increased albumin quotients (blood/
CSF barrier dysfunction) was calculated according to
QAlb > (4 +Age(y)/15) × 10-3 [3].
Quantification of MBL in serum and CSF
The concentration of MBL in serum was estimated via
its lectin activity measured with europium-labeled anti-
MBL antibody. A detailed description of buffers and
reagents has been given elsewhere [16]. In brief, mono-
clonal anti-MBL antibody was coated onto the surface of
microtiter wells. Plasma or serum samples, diluted 1:100
in a high ionic strength buffer (preventing coagulation),
calcium (needed for the binding of MBL), HSA (w/v)
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the wells. Following incubation the wells were washed
and europium-labeled anti-MBL antibody was added.
After another incubation and wash, enhancement buffer
was added and the bound europium was measured by
time-resolved fluorometry. Dilutions of standard serum
as well as samples of serum with known high (1046 ng
MBL/ml), middle (251 ng MBL/ml) and low (38 ng
MBL/ml) concentrations were included as internal con-
trols. The inter- assay coefficients of variation (CV), cal-
culated on 20 assays, were 8% and 11% respectively. The
concentration of CSF MBL levels was measured by the
same procedure as serum but using undiluted CSF
samples.
Statistics for the CSF/serum quotients
The CSF Statistics Tool was used, based on nonlinear
reference of the protein CSF/serum quotients to the
individual albumin quotient [15]. For details see also
legend of Figure 1. Statistics for the comparison of
inter-individual CV values were not used as there was
no data overlap of these groups.Table 1 CSF/serum quotients for albumin, IgG, IgA, IgM and M
in controls and patients with barrier dysfunctions
Normal Blood
Pat Q Alb× 103 Q IgG×103 Q IgA×103 Q IgM
1 6,8 2.9 1.5 0
2 3,4 1.6 0.6 0
3 6,0 2.9 1.5 <0
4 3,7 1.8 0.9 <0
5 7,0 3.2 1.9 0
6 4,9 2.3 0.8 0
7 5,0 2.2 1.3 0
8 6,2 2.7 1.3 <0
9 2,6 1.2 0.6 <0
10 5,6 3.0 1.7 0
11 3,4 1.5 0.6 0
12 4,1 2.2 1.1 <0
13 7,5 4.2 2.6 0
Blood CSF barrie
14 13.4 7.2 4.0 0
15 10.3 5.2 3.1 1
16 16.6 9.6 7.7 1
17 36.7 32.2 22.8 13
18 64.6 52.5 42.4 36
19 24.8 11.3 7.6 0
20 106 79.7 70.2 67
The control group (upper part) represents patients with normal CSF data and norm
blood-CSF barrier dysfunction without signs of an inflammation in brain.Results
Protein concentrations
The complete set of protein data for CSF and serum of
both groups (i.e., with and without a blood CSF barrier
dysfunction) is shown in Table 1. The corresponding
CSF/serum concentration quotients of MBL (QMBL,
Table 1) are shown as a function of the albumin quo-
tient, QAlb (Figure 2). The QIgM/QAlb quotient dia-
gram (Reibergram [2,3,5]) was used as a base for
Figure 2 to get a reliable hyperbolic reference range for a
theoretically blood-derived MBL fraction in CSF. The
free MBL molecule is a similar size to IgM, the reference
range of which was developed from a group of 4300
patients [1]. To obtain a reliable specific MBL diagram,
a much larger data set would be required, but according
to our results would have no diagnostic relevance. Nine
out of thirteen patients in the control group showed
QMBL values larger than the upper reference line Qlim
(Figure 2, bold line), some with intrathecal fractions lar-
ger than 80% of the total MBL concentration in CSF.
This clearly indicates that there is a dominant fraction of
MBL in CSF that does not originate from blood.BL with individual CSF and serum concentrations of MBL
CSF Barrier function
× 103 Q MBL×103 MBL-CSF ng/ml MBL-S ng/ml
.3 2,77 1,1 397
.1 1,33 1,31 979
.3 5,21 1,96 376
.2 0,39 0,2 514
.3 16,7 0,2 12
.2 0,34 1,58 4598
.2 1,58 1,15 728
.3 0,53 0,11 207
.1 0,27 0,27 985
.3 1,39 0,82 589
.1 6,00 1,82 303
.3 0,77 0,7 913
.5 33,8 1,15 34
r dysfunction
.5 12.75 0.88 69
.1 0.61 1.14 6784
.2 0.59 1.59 2678
.6 5.00 6.79 1346
.6 2.41 4.19 1739
.9 0.64 2.16 3391
.9 4.39 8.43 1921
al barrier function. The lower part represents the group of patients with a
Figure 2 Mannan-binding lectin (MBL) data in an IgM
Reibergram. The CSF/serum quotients QMBL are shown as a
function of the albumin quotients, QAlb, in a diagram with the
upper limit for the IgM molecule shown by the bold curve and with
the reference range for the IgM molecule which has a similar
molecular size as MBL. The filled squares represent the data of
normal controls and the open circles of patients with a barrier
dysfunction in the absence of an intrathecal immune response. 9/13
controls are obviously above the upper limit of the reference range,
i.e., they have an intrathecal MBL fraction over 80% of total CSF MBL
in addition to the blood-derived MBL fraction. The largest QMBL
values correspond to the lowest serum MBL values (Table 1). For
explanation of the diagram see legend to Figure 1 and [3]. The
diagram was created with the CSF Statistics Tool [15].
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From the statistics in Table 2 we get further systematic
information:
For MBL with a molecular weight of
6 × 96 kDa = 576 kDa, the mean transfer gradient was
similar to IgM. i.e., 3000:1 [1]. This would mean that
with a median concentration of about 500 ng/ml in
blood samples from the control group (Table 2), a blood
–derived mean CSF concentration of MBL of < 0.2 ng/ml
would be expected. In fact, there was a medianTable 2 Coefficients of variation (CV) of MBL data from
the control group with age-related albumin quotients in
Table 1 (median of n = 13)
QAlb×103 QMBL×103 CSF-MBLng/ml Serum MBLng/ml
Median
(n = 13)
5.0 1.39 1.1 514
Mean 5.1 0,73 0.95 818
SD 1.5 0,59 0.63 1183
CV (%) 30 81 66 146concentration > 1 ng/ml, which is 5 fold larger than
expected for a blood-derived fraction. This is indicative
for a predominantly brain-derived MBL fraction (> 80%)
in CSF.
The biological variability, expressed as the coefficient
of variation (CV), for MBL in CSF is much smaller
(CV= 66%) than that of the serum MBL value (CV=
146%). In the case of a blood-derived protein in CSF, an
increased coefficient of variation would be expected, due
to the additional biological variation originating from
the individual barrier function. These consequences of
the data in Table 2 mean that the CSF concentrations of
MBL were not, or only negligibly, correlated with the
serum concentrations. Therefore MBL in CSF is primar-
ily a brain-derived protein, i.e., it must be evaluated on
the base of its absolute concentration in CSF [4,6].
CSF flow-related MBL concentration in CSF
The correlation of the absolute CSF concentration of
MBL with the albumin CSF/serum quotient, QAlb, is
shown in Figure 3 for all patients without and with a
barrier dysfunction (Table 1). This diagram shows that
the MBL concentration in lumbar CSF increased with
increasing QAlb. This is a specific result, as only the
leptomeningeal proteins show such a dynamic, in con-
trast to neuronal or glial proteins the concentrations of
which are invariant to the increase of QAlb, i.e., the de-
crease of CSF flow rate. In combination with the results
described above, there is no other interpretation avail-
able than that MBL in lumbar CSF is a protein predom-
inantly derived from the leptomeninges. This result is
quantitatively explained by the theoretical model for
brain-derived proteins in CSF [1,4] and in this particular
case supported by morphological findings [17,18].Figure 3 CSF MBL concentration in lumbar CSF as a function of
the albumin quotient, QAlb. The regression line between CSF MBL
(ng/ml) and Q Alb × 103 refers to the data of all patients, the normal
control group and the group with blood-CSF barrier dysfunctions,
with the function: CSF MBL(ng/ml) = 0.61(ng/ml) + 0.075 QAlb.
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Sensitivity of MBL assays
The sufficiently sensitive analysis of MBL in CSF repre-
sents an analytical challenge [16]. For the analysis of
MBL in CSF it is important to use an ELISA coated with
MBL antibodies which has a higher affinity for MBL
compared to a mannan-coated ELISA.
Blood-CSF barrier function for MBL
In fact, we do not know the effective molecular size of
MBL, relevant for its passage from blood to CSF. The
blood-derived MBL fraction in CSF may be much smaller
than calculated on the base of the molecular size of free
MBL (results). It is possible that MBL with its tendency
to bind other proteins does not pass the blood CSF bar-
riers as a free MBL molecule but as a larger MBL-MASP
complex, i.e., with bound serine proteases [12,13]. If
this were the case, it would mean that much less than
20% of MBL in normal CSF originates from blood.
The intrathecal fraction of MBL
The intrathecal MBL fractions are shown directly in the
IgM quotient diagram in Figure 2. Due to its similar mo-
lecular size to MBL, the IgM diagram was used [1,3] for
a hypothetical evaluation of MBL data. On this basis
from Figure 2 it was concluded that MBL in CSF has a
large intrathecally synthesized fraction in most cases (9/
13 cases). As shown in Table 1 the largest QMBL values
in Figure 2 were associated with the smallest serum
values. This indicates that the CSF and serum values
have no biological correlation, i.e. the calculation of a
quotient is just a virtual number without a physical real-
ity. There is a second bias in the calculation of an intra-
thecal fraction with reference to the reference range in
Figure 2 for the molecular size of the free MBL mol-
ecule. The reference line in Figure 2 would be lower if
MBL passes the barriers as a larger MBL-MASP com-
plex, with the consequence of a larger intrathecal
fraction.
The coefficient of variation and the variation propagation
It may be a surprising application of the coefficient of
variation (CV) to characterize the connection of a par-
ameter in two different compartments of a biological
system.
If two independent functions contribute to the final re-
sult in mathematics this is treated as error propagation.
The variability of each function adds up to a common
larger variability. In physiology of protein dynamics this
means that the variability of a protein concentration in
blood samples of a group of persons is connected to the
independent variability of their individual barrier func-
tions (CSF flow rate, body length, CSF pressure, etc.)
additionally influencing the protein concentration inCSF. Due to such variation propagation there is a larger
variation in the albumin concentration in CSF samples
(CV= 26%) compared to the corresponding variation in
blood samples (CV= 15%) in a control group (N= 20,
mean age of 46 years, mean QAlb = 5.6 x10-3). Of course
there are different options in a biological system to get
such a result, but if the inverse combination with a
smaller or still equal variation in CSF compared to
serum samples of the same group is obtained, it can be
concluded that there is no diffusion-dependent associ-
ation of the parameter in the different compartments.
But this is exactly what was obtained for MBL (Table 2):
The coefficient of variation of MBL in CSF (CV= 66%)
was much smaller than the serum variability in this
group (CV= 146%). In spite of the small number, this
value is relevant as a similar result was obtained from
the data of a much larger group of blood donors
(N= 350) with a median of 1100 ng/ml and a coefficient
of variation CV= 128%.
So the CV data for MBL lead to the conclusion that
the MBL concentration in CSF does not vary in con-
cordance with the serum concentration (also obvious in
Table 1). This means that the CSF concentration of MBL
is derived predominantly from brain and follows the dy-
namics of brain-derived proteins.
Leptomeningeal proteins in CSF
Proteins released from leptomeningeal cells into CSF
(not by intercellular passage from blood as blood-
derived proteins) accumulate in CSF with decreasing
turnover rate, i.e. slower CSF flow rate. Correspondingly
their concentration correlates with QAlb. As shown for
beta trace protein the correlation with QAlb is linear, as
expected from the theory [4]. Figure 3 shows the corre-
sponding approach by which the absolute MBL CSF
concentration is shown as a function of the albumin
quotient. The result clearly indicates a dynamic typical
for a leptomeningeal protein. For testing the linearity for
the relation between CSF MBL and QAlb we would
need a larger number of data, but already with this small
number it is clear that the CSF MBL concentration is in-
creasing with increasing QAlb, i.e. the MBL concentra-
tion is definitely not invariant to the changing CSF flow
rate.
As a consequence of empirical data and theory [4] the
rostro-caudal gradient of leptomeningeal proteins should
increase, i.e., an increasing concentration of MBL be-
tween ventricular, cisternal and lumbar CSF could be
anticipated in the normal person. Such data would be
useful confirm or refute the above conclusions for MBL.
An important confirmation of our conclusions that
MBL is a leptomeningeal protein comes from histo-
chemical investigations in animals [17,18] which show
directly the presence of MBL in the leptomeninges.
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CSF as a predominantly leptomeningeal protein:
1. The CSF concentration of MBL is larger than
expected from a corresponding molecular size-
dependent passage from blood.
2. An intrathecal MBL fraction in CSF is observed in
more than 80% of the controls.
3. The smaller variability in CSF compared to blood
concentrations of MBL, i.e. the absence of variation
propagation, clearly excludes blood as the primary
source for the MBL concentration in CSF.
4. The dynamics of the absolute MBL concentration in
CSF as a (linear) function of QAlb point to a
leptomeningeal protein.
5. Morphological data from animals show that MBL
can be present in the leptomeninges.
Using established methods for evaluation of CSF
data [2,3,5,15], a theoretically-founded, physiologically-
relevant interpretation of the CSF flow-related dynam-
ics of MBL in CSF has been obtained for the first
time and the consequences for clinically relevant data
evaluation can be identified.
Conclusions
This study has shown that mannan-binding lectin in
CSF is predominantly brain-derived, most likely from
the leptomeningeal cells. There is a negligible physio-
logical connection between the MBL fractions in CSF
and serum. The evaluation of the clinical role of this
protein requires the measurement of absolute concentra-
tion in CSF as a function of the CSF/serum albumin
quotient. The recognition that MBL originates in brain
cells opens a new field of discussion about the function
of the innate immune response in CNS in acute and
chronic neurological diseases.
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